



MediWound to Report Fourth Quarter and Year End 2021 Financial Results and Host a Conference Call and Webcast on March 17, 2022

March 10, 2022

YAVNE, Israel, March 10, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the fourth quarter and year ended December 31, 2021 on Thursday, March 17 2022.

Following the release, MediWound's management will host a conference call and live webcast at 8:30 am Eastern Time to discuss the financial results, provide corporate updates and to answer questions. Dial-in and call details are as follows:

Conference Call & Webcast Details

Toll-Free: 877-602-7189
Israel: 1-809-315-362
International: 678-894-3057
Conference ID: 2281543
Webcast: [Click HERE](#)

To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call. An archived version of the webcast will be available for replay for 90 days in the Investors section of the MediWound website.

About MediWound Ltd.

MediWound is a biopharmaceutical company that develops, manufactures, and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Our strategy leverages our enzymatic technology platform, focused on next-generation bioactive therapies for burn care, wound care and tissue repair.

NexoBrid[®], our commercial orphan biological product for non-surgical eschar removal of deep-partial and full-thickness thermal burns, is a bromelain-based biological product containing a sterile mixture of proteolytic enzymes that selectively removes burn eschar within four hours without harming surrounding viable tissue. NexoBrid is currently marketed in the European Union and other international markets and is at registration-stage in the U.S. NexoBrid is supported by the U.S. Biomedical Advanced Research and Development Authority (BARDA).

EscharEx[®], our next-generation bioactive topical therapeutic under development in the U.S. for debridement of chronic and hard to heal wounds. In two Phase 2 studies, EscharEx was well-tolerated and has demonstrated safety and efficacy in the debridement of various chronic and other hard-to-heal wounds, within a few daily applications.

MW005, our topical biological drug for the treatment of non-melanoma skin cancers, is a clinical-stage product candidate under development.

Committed to innovation, we are dedicated to improving quality of care and patient lives. For more information, please visit www.mediwound.com.

Contacts:

Boaz Gur-Lavie
Chief Financial Officer
MediWound Ltd.
ir@mediwound.com

Monique Kosse
Managing Director, LifeSci Advisors
212-915-3820
monique@lifesciadvisors.com



Source: MediWound Ltd.